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Abstract
Background: Bleeding events have been associated with the use of antiplatelet agents. This study estimated the
incidence of bleeding events in patients previously hospitalized for a serious coronary event and determined the
risks of bleeding associated with the use of acetylsalicylic acid (ASA) and/or clopidogrel.
Methods: A UK primary care database was used to identify 27,707 patients aged 50 to 84 years, hospitalized for a
serious coronary event during 2000 to 2007 and who were alive 30 days later (start date). Patients were followed
up until they reached an endpoint (hemorrhagic stroke, upper or lower gastrointestinal bleeding [UGIB/LGIB]),
death or end of study [June 30, 2011]) or met an exclusion criterion. Risk factors for bleeding were determined in
a nested case-control analysis.
Results: Incidences of hemorrhagic stroke, UGIB, and LGIB were 5.0, 11.9, and 25.5 events per 10,000 person-years,
respectively, and increased with age. UGIB and LGIB led to hospitalization in 73 and 23 % of patients, respectively.
Non-users of ASA, who were mostly discontinuers, and current users of ASA had similar risks of hemorrhagic stroke,
UGIB, and LGIB. Users of combined antithrombotic therapy (warfarin and antiplatelets) experienced an increased risk
of hemorrhagic stroke (odds ratio [OR], 6.36; 95 % confidence interval [CI], 1.34–30.16), whereas users of combined
antiplatelet therapy (clopidogrel and ASA) experienced an increased risk of UGIB (OR, 2.42; 95 % CI, 1.09–5.36). An
increased risk of LGIB (OR, 1.86; 95 % CI, 1.34–2.57) was also observed in users of clopidogrel.
Conclusions: In patients previously hospitalized for a serious coronary event, combined antithrombotic therapy
was associated with an increased risk of hemorrhagic stroke, whereas combined antiplatelet therapy was associated
with an increased risk of UGIB.Non-use of ASA was rare in this population and use of ASA was not associated with
a significantly increased risk of hemorrhagic stroke, UGIB, or LGIB.
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Abbreviations: ASA, Acetylsalicylic acid; CI, Confidence interval; HR, Hazard ratio; LGIB, Lower gastrointestinal
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Background
Cardiovascular disease remains the principal cause of
mortality in Europe, being responsible for over 4 million
deaths each year [1]. For patients with acute coronary
syndrome (ST-elevation or non-ST-elevation myocardial
infarction, or unstable angina), resulting from occlusion
of the coronary arteries, long-term antiplatelet therapy
with low-dose acetylsalicylic acid (ASA) is recom-
mended, with the addition of a P2Y12-receptor inhibi-
tor, such as clopidogrel, for the first 12 months of
treatment [2, 3]. Dual antiplatelet therapy (ASA in
combination with a P2Y12-receptor inhibitor) is also
recommended after revascularization of the coronary
arteries [4]. These agents have been shown to reduce
the risk of recurrent cardiovascular events significantly
[5–9]. In addition to reducing cardiovascular risk, how-
ever, antiplatelet therapies confer an increased risk of
bleeding in general [6–8] and of upper gastrointestinal
bleeding (UGIB) in particular [10–12]. The risk of lower
gastrointestinal bleeding (LGIB) associated with antiplate-
let therapies, however, has rarely been studied and only in
small populations [13–15] or elderly patients [16].
We have conducted a retrospective cohort study with
nested case-control analyses in a large population to assess
the incidences of hemorrhagic stroke, UGIB, and LGIB in
patients who have survived a serious coronary event
(defined as myocardial infarction, unstable angina, or
revascularization of the coronary arteries). The effects of
treatment with low-dose ASA and clopidogrel, alone or in
combination, were evaluated, as well as the effects of other
demographic factors, comorbidities, and comedications.
Methods
Data source
Data were collected from The Health Improvement Net-
work (THIN), a computerized medical research database
containing systematically recorded, anonymized data on
over 3 million individuals currently registered with partici-
pating primary care practices in the UK [17]. Patients in-
cluded in the database are representative of the general
UK population with respect to age, sex, and geographical
region [18]. Information contained in THIN includes
patient demographics and details of consultations with
primary care physicians (PCPs), and data on consultant
referrals, hospitalizations, laboratory test results, diagno-
ses, and prescriptions. Read classification is used to code
specific diagnoses [19] and a drug dictionary based on
data from the Gemscript classification is used to code pre-
scriptions [20]. The validity of THIN for use in pharma-
coepidemiological research has been demonstrated [21].
Ethics statement
The company that owns THIN (Cegedim Strategic
Data) has received ethical approval from the South East
Research Ethics Committee to supply anonymized, pre-
collected, primary care data for scientific research. Pa-
tients can opt out of having their depersonalized records
collected; therefore, patient consent is not required when
working with anonymized records in THIN. This study
was approved by a multicenter research ethics committee
(REC reference: 09/H0305/90).
Study cohort
The selection of the study cohort has been described in
detail elsewhere [22]. Briefly, patients were identified
who were aged 50 to 84 years at any time between Janu-
ary 1, 2000 and December 31, 2007, who had also been
enrolled with their PCP for at least 1 year, and who had
at least 1 year of medical records available since their
first recorded prescription. Patients were excluded if
they had a diagnosis of cancer recorded before their start
date, or if they were aged 70 years or over and had been
enrolled with their PCP for more than 1 year and had
fewer than two health contacts during that time (proxy
for incomplete data recording). All individuals were
identified who had evidence of hospitalization for a ser-
ious coronary event (defined as myocardial infarction,
revascularization of the coronary arteries [elective and
non-elective percutaneous coronary intervention or cor-
onary artery bypass graft] or unstable angina) and who
were alive 30 days later (N = 27,707). Each patient’s start
date was set at 30 days after the date of hospitalization
for their coronary event. Although the original cohort
[22] included patients with data recorded in both THIN
and the Clinical Practice Research Datalink databases,




To identify cases of hemorrhagic stroke, we followed up
all patients in the study cohort from their start date until
June 30, 2011, or until they reached one of the following
endpoints: diagnosis of hemorrhagic stroke; met an
exclusion criterion (diagnosis of cancer, alcohol abuse,
or reached 85 years of age); death; or no further contri-
bution from their PCP to THIN. The anonymized pro-
files of all patients with a Read code suggestive of
hemorrhagic stroke were reviewed manually to ascertain
genuine cases. The definition of hemorrhagic stroke was
the same as that used in a recent population-based study
[23]. Potential cases were discarded if: they had a Read
code suggestive of hemorrhagic stroke, but that was not
confirmed later; the stroke was ischemic rather than
hemorrhagic; the episode was not a primary event (e.g. if
it was secondary to trauma); the patient had experienced
subdural hemorrhage; the stroke had occurred in a hos-
pital setting; or they were prescribed an antiplatelet or oral
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anticoagulant in the 60 days following the event. For those
with hemorrhagic stroke, the date of hospitalization was
considered the index date.
Gastrointestinal bleeding
For the analysis of patients who had experienced UGIB or
LGIB, we excluded all patients with a history of esopha-
geal varices, Mallory–Weiss syndrome, chronic liver dis-
ease, or coagulopathies recorded before their start date.
All patients free from these comorbidities were followed
up from their start date until June 30, 2011, or until they
reached one of the following endpoints: diagnosis of UGIB
or LGIB; met an exclusion criterion (cancer, esophageal
varices, Mallory–Weiss syndrome, chronic liver disease or
coagulopathy diagnoses, alcohol abuse, or reached the age
of 85 years); death; or no further contribution from their
PCP to THIN. The anonymized profiles of all patients
with a Read code suggestive of UGIB or LGIB were
reviewed manually to ascertain genuine cases. At this
stage, all patients who had been hospitalized for a non-
gastrointestinal event in the month before their UGIB or
LGIB diagnosis were also excluded, as were all patients
who met an exclusion criterion in the 2 months after their
UGIB or LGIB diagnosis. Confirmed cases of UGIB were
all individuals who had been referred to a consultant or
admitted to hospital, for whom the site of bleeding or per-
foration was the stomach or duodenum. Patients whose
site of bleeding or perforation was the esophagus were
excluded. Confirmed cases of LGIB were all those who
had been referred to a consultant or admitted to hospital,
for whom the cause of bleeding had been identified
(diverticulosis, polyposis, inflammatory bowel disease, is-
chemic colitis, etc.) and the site of bleeding or perforation
was the jejunum, ileum, colon, or rectum. Cases of
bleeding due to hemorrhoids were discarded. To validate
cases of LGIB further, questionnaires were sent to the
PCPs of a random sample of 124 potential LGIB cases
requesting all information related to that event. This ap-
proach was previously used for ascertainment of cases of
hemorrhagic stroke [23] and UGIB [24]. We received
questionnaires with information for 101 LGIB cases (re-
sponse rate, 81.5 %). Most of these cases (83/101) were
confirmed after reviewing the information sent, yielding a
positive predictive value of 82.2 %. We could not confirm
the LGIB diagnoses in the other 18 cases (hemorrhoids/
anal fissure identified as the cause of bleeding [n = 12] or
no clear cause of bleeding identified [n = 6]). For all
patients with either UGIB or LGIB, the date of the first
objective sign of the bleeding episode was considered the
index date.
Control selection
For all patients in the study cohort, a random date was
generated during the study period. If that random date
fell within their follow-up period, they were eligible to
be considered as a control and the random date was
considered to be their index date. From this total set of
eligible controls, three random control groups were se-
lected, frequency matched by age (within 1 year), sex,
and calendar year to the groups of patients with
hemorrhagic stroke, UGIB, or LGIB. For comparison
with patients with hemorrhagic stroke and UGIB, dif-
ferent control groups comprising 1,000 individuals were
selected. For comparison with patients with LGIB, a con-
trol group comprising 2,000 individuals was selected.
Categorization of drug use
Exposure to drugs was classified as ‘current’ when the
supply of the most recent prescription lasted until the
index date or ended in the month before the index
date, ‘recent’ when it ended between 1 month and
3 months before the index date, ‘past’ when it ended
between 3 months and 1 year before the index date,
and ‘non-use’ when there was no recorded use in the
year before the index date. Duration of use was defined
according to the time period of ‘consecutive’ prescrip-
tions. Prescriptions were considered to be consecutive
when the time interval between the end of the supply
of the first and the beginning of supply of the second
was less than 2 months. Treatment duration was cate-
gorized as no more than 1 month, 1 month to 1 year,
and greater than 1 year. Only prescriptions issued after
the start date were considered when estimating drug
exposure. In the nested case-control analyses, use of
ASA and use of clopidogrel include the use of each
drug alone and in combination with each other, unless
otherwise stated.
Statistical analysis
Odds ratios (ORs), 95 % confidence intervals (CIs) and
P values (Wald tests), calculated using unconditional
logistic regression models, were used to determine the
association between the use of ASA or clopidogrel and
the occurrence of hemorrhagic stroke, UGIB, or LGIB.
Models were adjusted for frequency-matched variables
(age, sex, and calendar year), length of follow-up,
health services utilization (PCP visits, referrals, and
hospitalizations), smoking, type of coronary event, his-
tory of peptic ulcer disease, and use of proton pump
inhibitors (PPIs), ASA, clopidogrel, non-steroidal anti-
inflammatory drugs (NSAIDs), and warfarin. The ef-
fects of patient demographics and baseline characteris-
tics, comorbidities, and comedications on bleeding
events were also assessed. Due to the method used to
select controls, ORs are unbiased estimates of rate ra-
tios in the underlying study cohort.
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Results
Incidence of hemorrhagic stroke, LGIB, and UGIB
The study cohort comprised 27,707 individuals, with a
mean age of 67.7 years (Table 1). There were more men
than women (68.2 % vs. 31.8 %). The qualifying event
was a myocardial infarction for 58.1 % of patients,
unstable angina for 6.9 % and elective revascularization
for 34.9 %. During follow-up, a total of 70 patients had a
hemorrhagic stroke (mean follow-up: 5.0 years; standard
deviation [SD]: 3.0 years), 152 experienced UGIB (mean
follow-up: 4.6 years; SD: 3.0 years), and 316 experienced
LGIB (mean follow-up: 4.5 years; standard deviation
[SD]: 3.0 years). Among patients who had a hemorrhagic
stroke, 48 experienced intracerebral hemorrhage and 22
had a subarachnoid hemorrhage. Among the 152 UGIB
cases, the site of bleeding was gastric in 80 patients,
duodenal in 47, and gastroduodenal in 16, while it was
undefined in nine individuals. In total, 111 (73 %) pa-
tients with UGIB were hospitalized and distributions of
bleeding sites were similar in hospitalized and non-
hospitalized patients (Additional file 1). The most com-
mon causes of LGIB were diverticular disease (n = 201),
polyps (n = 54), and inflammatory bowel disease (n = 49),
accounting for 96.2 % of LGIB cases, and 72 (23 %) pa-
tients were hospitalized following LGIB. Causes of LGIB
were similar in hospitalized and non-hospitalized pa-
tients (Additional file 2).
Overall, incidences of bleeding events were 5.0 (95 %
CI, 3.9–6.3) per 10,000 person-years for hemorrhagic
stroke, 11.9 (95 % CI, 10.1–13.9) per 10,000 person-
years for UGIB, and 25.5 (95 % CI, 22.7–28.4) per
10,000 person-years for LGIB (Fig. 1). The correspond-
ing incidences of fatal bleeding events (death within
1 month of the bleed) were 2.2 (95 % CI, 1.5–3.1), 0.5
(95 % CI, 0.2–1.1), and 0.5 (95 % CI, 0.2–1.1) cases per
10,000 person-years, respectively. When only hospital-
ized patients were considered, the incidences of UGIB
and LGIB were 8.7 (95 % CI, 7.1–10.4) and 5.8 (95 % CI,
4.5–7.3) events per 10,000 person-years, respectively.
When broken down according to age and sex, the inci-
dence of all three categories of bleeding event increased
with age (Fig. 1b). For hemorrhagic stroke, the incidence
was higher in women than in men for individuals aged
50 to 64 years (7.5 vs. 1.5 events per 10,000 person-
years). However, for patients aged 75 to 84 years, this
trend was reversed (5.9 and 9.7 events per 10,000
person-years for women and men, respectively). For
UGIB, the incidence was similar in men and women in
all age categories, while for LGIB the incidence was
higher in women than in men in all age groups (19.1
vs. 16.5, 30.2 vs. 21.8, and 42.8 vs. 30.0 events per
10,000 person-years for individuals aged 50 to 64 years,
65 to 74 years, and 75 to 84 years, respectively). The
overall incidence of bleeding events was 42.4 per
Table 1 Patient demographics and baseline characteristics of the study cohort, and three sets of cases and controls
Study cohort Hemorrhagic stroke UGIB LGIB












Sex Male 18,887 (68.2) 45 (64.3) 668 (66.8) 102 (67.1) 681 (68.1) 191 (60.4) 1,369 (68.5)
Female 8,820 (31.8) 25 (35.7) 332 (33.2) 50 (32.9) 319 (31.9) 125 (39.6) 631 (31.6)
Age, years 50–59 5,929 (21.4) 5 (7.1) 59 (5.9) 13 (8.6) 75 (7.5) 30 (9.5) 241 (12.1)
60–69 9,323 (33.6) 16 (22.9) 237 (23.7) 41 (27.0) 277 (27.7) 82 (25.9) 621 (31.1)
70–79 9,545 (34.4) 30 (42.9) 456 (45.6) 66 (43.4) 436 (43.6) 144 (45.6) 832 (41.6)
80–84 2,910 (10.5) 19 (27.1) 248 (24.8) 32 (21.1) 212 (21.2) 60 (19.0) 306 (15.3)
BMI, kg/m2 <20 632 (2.3) 6 (8.6) 35 (3.5) 6 (3.9) 22 (2.2) 10 (3.2) 61 (3.0)
20–24 6,419 (23.2) 17 (24.3) 249 (24.9) 36 (23.7) 246 (24.6) 65 (20.6) 441 (22.1)
25–29 10,645 (38.4) 21 (30.0) 413 (41.3) 64 (42.1) 414 (41.4) 139 (44.0) 868 (43.4)
≥30 6,328 (22.8) 21 (30.0) 258 (25.8) 39 (25.7) 284 (28.4) 89 (28.2) 546 (27.3)
Unknown 3,683 (13.3) 5 (7.1) 45 (4.5) 7 (4.6) 34 (3.4) 13 (4.1) 84 (4.2)
History of peptic ulcer diseasea None 25,077 (90.5) 56 (80.0) 867 (86.7) 109 (71.7) 876 (87.6) 277 (87.7) 1,824 (91.2)
Uncomplicated 1,615 (5.8) 11 (15.7) 96 (9.6) 28 (18.4) 97 (9.7) 27 (8.5) 119 (6.0)
Complicated 1,015 (3.7) 3 (4.3) 37 (3.7) 15 (9.9) 27 (2.7) 12 (3.8) 57 (2.9)
Qualifying serious coronary event Myocardial infarction 16,107 (58.1) 47 (67.1) 586 (58.6) 81 (53.3) 587 (58.7) 161 (50.9) 1,110 (55.5)
Unstable angina 1,919 (6.9) 4 (5.7) 69 (6.9) 14 (9.2) 74 (7.4) 36 (11.4) 140 (7.0)
Elective revascularization 9,681 (34.9) 19 (27.1) 345 (34.5) 57 (37.5) 339 (33.9) 119 (37.7) 750 (37.5)
Data are presented as n (%)
BMI body mass index, LGIB lower gastrointestinal bleeding, UGIB upper gastrointestinal bleeding
aDiagnosed any time before the serious coronary event
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10,000 person–years for any bleeding event and 3.2
cases per 10,000 person–years for fatal bleeding events.
Nested case-control analyses
In nested case-control analyses, no associations were seen
between current use of ASA and risk of hemorrhagic
stroke (Table 2) or LGIB (Table 3). A non-significant in-
creased risk of UGIB was observed among current users
of ASA (Table 4). For patients receiving a dose of 300 mg
(n = 15), however, ASA use was associated with a signifi-
cant increase in the risk of hemorrhagic stroke (OR, 8.23;
95 % CI, 1.77–38.26). No significant associations were
seen between the use of clopidogrel and the risk of
hemorrhagic stroke. In contrast, current clopidogrel use
was associated with a significant increase in the risk of
UGIB (OR, 2.17; 95 % CI, 1.35–3.49) and LGIB (OR, 1.86;
95 % CI, 1.34–2.57). The use of dual antiplatelet therapy
was associated with a significant increase in the risk of
UGIB (OR, 2.42; 95 % CI, 1.09–5.36) and a non-
significant increase in the risk of LGIB (OR, 1.63; 95 %
CI, 0.95–2.81). Results from nested–control analyses
were similar when only hospitalized cases of UGIB and
LGIB (n = 111 and n = 72, respectively) were considered
(Additional files 3 and 4). Additionally we found that
individuals using warfarin (OR, 3.71; 95 % CI, 1.66–
8.28) or combined antithrombotic therapy with war-
farin and antiplatelets (OR, 6.36; 95 % CI: 1.34–30.16)
experienced a greatly increased risk of hemorrhagic
stroke, but not of UGIB or LGIB (Tables 5, 6, and 7).
Other comorbidities and current drug use found to be
significantly associated with hemorrhagic stroke, UGIB,
and LGIB are listed in Table 8. The largest increase in
Fig. 1 Incidence of (a) UGIB and LGIB, according to hospitalization status and (b) hemorrhagic stroke, UGIB, and LGIB, according to age and sex.
LGIB lower gastrointestinal bleeding, UGIB upper gastrointestinal bleeding
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risk of hemorrhagic stroke was seen in patients who had
a history of hemorrhagic stroke before the study period
(OR, 23.35; 95 % CI, 5.11–106.73), although this obser-
vation was based on a small number of patients. Risk of












Non-use 20 (28.6) 164 (16.4) 1 (−)
Current use 44 (62.9) 753 (75.3) 0.88 (0.42–1.85) 0.74
Duration
< 1 month 3 (4.3) 29 (2.9) 0.77 (0.11–5.56) 0.80
1–12 months 16 (22.9) 201 (20.1) 0.71 (0.26–1.96) 0.51
≥ 1 year 25 (35.7) 523 (52.3) 1.15 (0.50–2.66) 0.74
Dose
75 mg/day 39 (55.7) 672 (67.2) 0.88 (0.41–1.86) 0.74
150 mg/day 1 (1.4) 70 (7.0) 0.19 (0.02–1.66) 0.13
300 mg/day 4 (5.7) 11 (1.1) 8.23 (1.77–38.26) 0.01
Recent use 2 (2.9) 44 (4.4) 0.51 (0.10–2.69) 0.43
Past use 4 (5.7) 39 (3.9) 1.02 (0.30–3.47) 0.98
Clopidogrel
Non-use 50 (71.4) 757 (75.7) 1 (−)
Current use 16 (22.9) 168 (16.8) 1.49 (0.70–3.17) 0.30
Duration
< 1 month 3 (4.3) 18 (1.8) 2.09 (0.32–13.67) 0.44
1–12 months 7 (10.0) 75 (7.5) 0.99 (0.35–2.78) 0.98
≥ 1 year 6 (8.6) 75 (7.5) 2.42 (0.81–7.22) 0.11
Dose
75 mg/day 16 (22.9) 156 (15.6) 1.61 (0.75–3.45) 0.22
≥ 150 mg/day 0 (0.0) 12 (1.2)
Recent use 3 (4.3) 19 (1.9) 1.34 (0.33–5.49) 0.68




13 (18.6) 96 (9.6) 1 (−)
Current use of both
ASA and clopidogrel








9 (12.9) 77 (7.7) 2.20 (0.72–6.71) 0.17
ASA acetylsalicylic acid, CI confidence interval, NSAID non-steroidal anti-
inflammatory drug, PCP primary care physician, PPI proton pump inhibitor
aAdjusted according to age, sex, calendar year, length of follow-up, health
services utilization (PCP visits, referrals and hospitalizations), smoking, type of
coronary event, history of peptic ulcer disease, and use of PPIs, ASA, clopidogrel,
NSAIDs and warfarin












Non-use 74 (23.4) 370 (18.5) 1 (−)




< 1 month 11 (3.5) 65 (3.3) 0.79 (0.35–1.80) 0.57
1–12 months 97 (30.7) 441 (22.1) 1.20 (0.79–1.82) 0.40
≥ 1 year 114 (36.1) 996 (49.8) 0.83 (0.56–1.22) 0.34
Dose
75 mg/day 193 (61.1) 1286
(64.3)
0.96 (0.68–1.36) 0.81
150 mg/day 22 (7.0) 178 (8.9) 0.90 (0.51–1.57) 0.70
300 mg/day 7 (2.2) 38 (1.9) 1.30 (0.52–3.21) 0.57
Recent use 10 (3.2) 59 (3.0) 1.12 (0.51–2.44) 0.77
Past use 10 (3.2) 69 (3.5) 0.76 (0.36–1.60) 0.47
Clopidogrel
Non-use 200 (63.3) 1529
(76.5)
1 (−)
Current use 95 (30.1) 318 (15.9) 1.86 (1.34–2.57) <0.01
Duration
< 1 month 9 (2.8) 25 (1.3) 2.40 (0.94–6.13) 0.07
1–12 months 44 (13.9) 148 (7.4) 1.51 (0.97–2.36) 0.07
≥ 1 year 42 (13.3) 145 (7.3) 2.12 (1.37–3.27) <0.01
Dose
75 mg/day 84 (26.6) 286 (14.3) 1.82 (1.30–2.55) <0.01
≥ 150 mg/day 11 (3.5) 32 (1.6) 2.15 (1.01–4.58) 0.05
Recent use 8 (2.5) 40 (2.0) 1.30 (0.58–2.94) 0.52




40 (12.7) 237 (11.9) 1 (−)
Current use of both
ASA and clopidogrel










38 (12.0) 128 (6.4) 1.56 (0.88–2.74) 0.13
ASA acetylsalicylic acid, CI confidence interval, LGIB lower gastrointestinal bleeding,
NSAID non-steroidal anti-inflammatory drug, PCP primary care physician, PPI proton
pump inhibitor
aAdjusted according to age, sex, calendar year, length of follow-up, health services
utilization (PCP visits, referrals and hospitalizations), smoking, type of coronary
event, history of peptic ulcer disease and use of PPIs, ASA, clopidogrel, NSAIDs
and warfarin
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hemorrhagic stroke was also increased in patients who
had been hospitalized at least once for any reason in
the year before the index date, and in those who were
currently using any NSAID. UGIB was most strongly
associated with having valvular heart disease (OR, 3.73;
95 % CI, 1.95–7.11) or complicated peptic ulcer disease
(OR, 3.71; 95 % CI, 1.76–7.84). The strongest associ-
ation with risk of LGIB was seen for pancreatic disease
(OR, 4.49; 95 % CI, 1.20–16.74), although this observa-
tion was based on only a small number of patients.
Discussion
We have shown that, in the period 2000 to 2007, among
nearly 30,000 patients who were hospitalized for a serious
coronary event (myocardial infarction, revascularization of
the coronary arteries, or unstable angina) and who were
alive 30 days later, the incidence of hemorrhagic stroke,
UGIB, and LGIB up to 2011 was 5.0, 11.9, and 25.5 events
per 10,000 person-years, respectively. Incidence increased
with age for all three categories of bleeding events. To
our knowledge, this is the first population-based study
to report absolute risk of these three types of bleeding
events in patients hospitalized for a coronary event.
The use of a primary care database affords valuable
insight into the burden of bleeding events and our
results suggest that the sole use of hospital records for
identification of gastrointestinal bleeding events may
severely underestimate their incidence, particularly for
LGIB. In our study, more than three quarters of












Non-use 29 (19.1) 186 (18.6) 1 (−)
Current use 107 (70.4) 753 (75.3) 1.31 (0.76–2.27) 0.33
Duration
< 1 month 8 (5.3) 32 (3.2) 0.92 (0.29–2.91) 0.89
1–12 months 38 (25.0) 191 (19.1) 1.26 (0.62–2.57) 0.53
≥ 1 year 61 (40.1) 530 (53.0) 1.39 (0.72–2.67) 0.33
Dose
75 mg/day 98 (64.5) 653 (65.3) 1.40 (0.80–2.43) 0.23
150 mg/day 6 (3.9) 85 (8.5) 0.53 (0.18–1.59) 0.26
300 mg/day 3 (2.0) 15 (1.5) 2.47 (0.60–10.24) 0.21
Recent use 10 (6.6) 24 (2.4) 4.33 (1.61–11.66) <0.01
Past use 6 (3.9) 37 (3.7) 0.85 (0.30–2.44) 0.76
Clopidogrel
Non-use 96 (63.2) 765 (76.5) 1 (−)
Current use 48 (31.6) 164 (16.4) 2.17 (1.35–3.49) <0.01
Duration
< 1 month 10 (6.6) 11 (1.1) 5.76 (1.82–18.27) <0.01
1–12 months 25 (16.4) 73 (7.3) 2.14 (1.10–4.18) 0.03
≥ 1 year 13 (8.6) 80 (8.0) 1.80 (0.85–3.80) 0.12
Dose
75 mg/day 46 (30.3) 154 (15.4) 2.22 (1.38–3.59) <0.01
≥ 150 mg/day 2 (1.3) 10 (1.0) 1.19 (0.22–6.31) 0.84
Recent use 2 (1.3) 13 (1.3) 1.12 (0.22–5.64) 0.89
















12 (7.9) 64 (6.4) 1.29 (0.52–3.20) 0.58
ASA acetylsalicylic acid, CI confidence interval, NSAID non-steroidal anti-
inflammatory drug, PCP primary care physician, PPI proton pump inhibitor,
UGIB upper gastrointestinal bleeding
aAdjusted according to age, sex, calendar year, length of follow-up, health
services utilization (PCP visits, referrals and hospitalizations), smoking, type
of coronary event, history of peptic ulcer disease and use of PPIs, ASA,
clopidogrel, NSAIDs and warfarin












Non-useb 50 (71.4) 904 (90.4) 1 (−)
Current use 17 (24.3) 83 (8.3) 3.71 (1.66–8.28) <0.01
< 1 month 1 (1.4) 4 (0.4) 2.99 (0.27–32.88) 0.37
1–12 months 5 (7.1) 30 (3.0) 2.14 (0.64–7.08) 0.21
> 1 year 11 (15.7) 49 (4.9) 6.26 (2.37–16.52) <0.01
Recent use 2 (2.9) 5 (0.5) 9.21 (1.43–59.26) 0.02




3 (4.3) 44 (4.4) 1 (−)
Current AP and
non-current warfarin
46 (65.7) 810 (81.0) 0.93 (0.26–3.32) 0.92
Non-current AP and
current warfarin
10 (14.3) 63 (6.3) 2.26 (0.54–9.47) 0.26
Current AP and
current warfarin
7 (10.0) 20 (2.0) 6.36 (1.34–30.16) 0.02
AP antiplatelets
aEstimates adjusted by age, sex, calendar year, time of follow up after serious
coronary event, health services utilisation, smoking, proton pump inhibitor,
antithrombotic and nonsteroidal anti-inflammatory drug use, type of serious
coronary event and prior peptic ulcer disease using a logistic regression model
bReference category
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patients with LGIB were referred to a consultant, but
not hospitalized.
With regard to drug use, we did not observe statisti-
cally significant associations between the risk of
hemorrhagic stroke and current use of low-dose ASA
for doses of 75 mg or 150 mg per day, relative to non-
use. A dose of 300 mg per day, however, was associated
with a significant increase in the risk of hemorrhagic
stroke, but this association was based on a small number
of users. Current use of clopidogrel, with or without
concomitant low-dose ASA, was not significantly associ-
ated with the risk of hemorrhagic stroke. However, the
combined use of warfarin and antiplatelets was associ-
ated with a greatly increased risk of hemorrhagic stroke.
Current use of clopidogrel was associated with a sig-
nificantly increased risk of UGIB and LGIB. Current use
of low-dose ASA did not show a significant association
with either UGIB or LGIB. Dual antiplatelet therapy was
associated with a significant increase in the risk of UGIB
and a non-significant increase in the risk of LGIB.
The increased risk of UGIB and LGIB seen among
patients receiving clopidogrel, and the significant associ-
ation between UGIB and the use of dual antiplatelet
therapy, are in line with the previous evidence that use
of antiplatelet therapies increases the risk of bleeding
events [6–8, 10–12]. Previous studies have reported an
increased risk of bleeding events with clopidogrel
combined with low-dose ASA therapy compared with
monotherapy. In a randomized study in patients with
non-ST-segment elevation myocardial infarctions, major
bleeding events were significantly more common with
clopidogrel combined with ASA than with ASA alone
(relative risk [RR], 1.38; 95 % CI, 1.13–1.67). Major gastro-
intestinal bleeding events were more frequent with dual
antiplatelet therapy than with ASA monotherapy, but
frequency of intracranial bleeding events did not differ
between the groups [6]. In another randomized study,
dual antiplatelet therapy was associated with significantly
higher rates of major gastrointestinal bleeding and of
intracranial bleeding than clopidogrel monotherapy in
high-risk patients following a recent ischemic stroke or
transient ischemic attack [25].
A previous analysis of individuals with UGIB identified
from THIN showed that dual antiplatelet therapy with
clopidogrel in combination with low-dose ASA was as-
sociated with an increased risk of UGIB compared with
low-dose ASA alone (RR, 2.08; 95 % CI, 1.34–3.21).
Current clopidogrel use was also associated with an in-
creased risk of UGIB compared with non-use, as was the
current use of low-dose ASA [11]. An analysis using the
National Health Insurance Database in Taiwan identified
clopidogrel use as a significant factor for increased risk












Non-useb 276 (87.3) 1813 (90.6) 1 (−)
Current use 32 (10.1) 157 (7.8) 1.10 (0.69–1.78) 0.68
< 1 month 3 (0.9) 8 (0.4) 1.55 (0.38–6.34) 0.54
1–12 months 15 (4.7) 44 (2.2) 1.78 (0.89–3.55) 0.10
> 1 year 14 (4.4) 105 (5.3) 0.73 (0.38–1.40) 0.34
Recent use 2 (0.6) 11 (0.5) 0.91 (0.19–4.42) 0.91




18 (5.7) 128 (6.4) 1 (−)
Current AP and
non-current warfarin
252 (79.7) 1596 (79.8) 1.00 (0.59–1.71) 1.00
Non-current AP and
current warfarin
24 (7.6) 116 (5.8) 1.01 (0.50–2.02) 0.99
Current AP and
current warfarin
8 (2.5) 41 (2.1) 0.89 (0.35–2.30) 0.82
AP antiplatelets
aEstimates adjusted by age, sex, calendar year, time of follow up after serious
coronary event, health services utilisation, smoking, proton pump inhibitor,
antithrombotic and nonsteroidal anti-inflammatory drug use, type of serious
coronary event and prior peptic ulcer disease using a logistic regression model
bReference category












Non-useb 128 (84.2) 887 (88.7) 1 (−)
Current use 23 (15.1) 102 (10.2) 1.79 (0.94–3.41) 0.08
< 1 month 5 (3.3) 5 (0.5) 7.76 (1.69–35.68) 0.01
1–12 months 8 (5.3) 43 (4.3) 0.99 (0.40–2.47) 0.98
> 1 year 10 (6.6) 54 (5.4) 2.11 (0.83–5.33) 0.11
Recent use 1 (0.7) 5 (0.5) 1.83 (0.19–17.60) 0.60




10 (6.6) 55 (5.5) 1 (−)
Current AP and
non-current warfarin
107 (70.4) 789 (78.9) 0.68 (0.31–1.49) 0.34
Non-current AP and
current warfarin
11 (7.2) 74 (7.4) 0.66 (0.24–1.85) 0.43
Current AP and
current warfarin
12 (7.9) 28 (2.8) 1.67 (0.56–4.96) 0.35
AP antiplatelets
aEstimates adjusted by age, sex, calendar year, time of follow up after serious
coronary event, health services utilisation, smoking, proton pump inhibitor,
antithrombotic and nonsteroidal anti-inflammatory drug use, type of serious
coronary event and prior peptic ulcer disease using a logistic regression model
bReference category
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of both UGIB (hazard ratio [HR], 3.66; 95 % CI, 2.96–
4.51) and LGIB (HR, 3.52; 95 % CI, 2.74–4.52) [26].
Similarly, a meta-analysis of randomized controlled trials
showed that low-dose ASA was associated with a signifi-
cant increase in the risk of major gastrointestinal bleed-
ing compared with placebo [27]. An increased risk of
UGIB was also reported with use of low-dose ASA in
meta-analyses of randomized controlled trials and of
observational studies [28].
This failure to detect a statistically significant in-
creased risk of UGIB or LGIB associated with ASA in
our study could be related to the nature of the study
cohort. We started following up patients who had just
been hospitalized for a serious coronary event. ASA is
generally started in these patients as a result of this
event, and most individuals continue to receive ASA
therapy for years. In fact, current ASA use was over
75 % among controls and only about 10 % never used
ASA between their start and index dates. The relatively
small proportion (25 %) of those who were not current
users of ASA were mostly discontinuers and are likely
to differ in many ways from the rest; their background
risk of gastrointestinal bleeding could be much higher
than non-users of ASA in the general population. This
could explain the absence of an increased risk of UGIB
or LGIB with low-dose ASA in our population.








Hemorrhagic stroke (n = 70)
Comorbiditiesb
History of hemorrhagic stroke 4 (5.7) 5 (0.5) 23.35 (5.11–106.73) <0.01
≥ 1 hospitalization in the year before index datec 35 (50.0) 282 (28.2) 1.93 (1.06–3.49) 0.03
Current drug used
Diuretics 21 (30.0) 376 (37.6) 0.52 (0.28–0.99) 0.05
NSAIDs 9 (12.9) 70 (7.0) 2.53 (1.12–5.68) 0.03
UGIB (n = 152)
Comorbiditiesb
Complicated peptic ulcer disease 15 (9.9) 27 (2.7) 3.71 (1.76–7.84) <0.01
Uncomplicated peptic ulcer disease 28 (18.4) 97 (9.7) 1.71 (1.02–2.86) 0.04
Valvular heart disease 22 (14.5) 50 (5.0) 3.73 (1.95–7.11) <0.01
≥ 1 hospitalization in year before index datec 84 (55.3) 262 (26.2) 2.50 (1.62–3.86) <0.01
Current drug used
NSAIDs 23 (15.1) 80 (8.0) 2.25 (1.27–3.96) 0.01
PPIs 68 (44.7) 316 (31.6) 1.62 (1.06–2.47) 0.03
LGIB (n = 316)
Comorbiditiesa
Pancreatic disease 4 (1.3) 8 (0.4) 4.49 (1.20–16.74) 0.03
Unstable angina 75 (23.7) 283 (14.1) 1.86 (1.25–2.77) <0.01
Dyspepsia 104 (32.9) 390 (19.5) 1.64 (1.23–2.18) <0.01
Diabetes mellitus 46 (14.6) 343 (17.2) 0.62 (0.43–0.88) 0.01
≥ 1 hospitalization in year before index datec 142 (44.9) 575 (28.7) 1.33 (0.98–1.79) 0.06
Current drug used
Calcium-channel blockers 112 (35.4) 544 (27.2) 1.34 (1.02–1.75) 0.03
NSAIDs 39 (12.3) 167 (8.3) 1.52 (1.02–2.25) 0.04
PPIs 147 (46.5) 621 (31.1) 1.60 (1.22–2.10) <0.01
ASA acetylsalicylic acid, CI confidence interval, DVT deep vein thrombosis, LGIB lower gastrointestinal bleeding, NSAID non-steroidal anti-inflammatory drug, PCP
primary care physician, PPI proton pump inhibitor, UGIB upper gastrointestinal bleeding
aAdjusted according to age, sex, calendar year, length of follow-up, health services utilization (PCP visits, referrals and hospitalizations), smoking, type of coronary
event, history of peptic ulcer disease and use of PPIs, ASA, clopidogrel, NSAIDs and warfarin
bRelative to absence of the respective comorbidity
cRelative to none
dRelative to non-use
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Our study showed a significant association between
the risk of hemorrhagic stroke and the use of ASA
300 mg per day, consistent with findings from previous
studies. A meta-analysis of 11 randomized controlled tri-
als reported a significantly increased risk of intracranial
bleeding with low-dose ASA compared with placebo
(RR, 1.65; 95 % CI, 1.12–2.44) [27]. However, this ana-
lysis showed no evidence for differences in the risk of
intracranial bleeding (or other bleeding endpoints) be-
tween lower-dose (75–162.5 mg per day) and higher-dose
(>162.5–325 mg per day) ASA, although it was limited by
the small number of patients receiving higher-dose ASA.
In contrast, results from a previous population-based
study involving 3,137 cases of hemorrhagic stroke showed
that long-term use of low-dose ASA was associated with a
decreased risk of subarachnoid hemorrhage [29]. The
small number of events in the current study did not allow
for separate analyses by type of hemorrhagic stroke.
We have shown that individuals using combined anti-
thrombotic therapy with warfarin and antiplatelets had a
greatly increased risk of hemorrhagic stroke. In our
previous population-based study we observed a similar
six-fold increased risk of intracerebral hemorrhage
among individuals using warfarin along with two or
more antiplatelet drugs [29]. These new data seem to
confirm that the increased risk of hemorrhagic stroke
observed for combined antithrombotic therapy exceeds
the risk of warfarin alone. Furthermore, a recent meta-
analysis of randomized trials and observational studies
in patients undergoing percutaneous coronary interven-
tion found that the incidence of major bleeding was
higher among individuals using triple therapy (combined
use of two antiplatelets with an oral anticoagulant) than
among those using dual antiplatelet therapy [30].
Although our nested case-control analyses were ad-
justed for known risk factors for bleeding events, we
cannot rule out some residual confounding by indica-
tion. It remains possible that patients at increased risk
of hemorrhagic stroke, UGIB, or LGIB are less likely to
be prescribed low-dose ASA owing to the known risk
associated with its use. Confounding by indication is
also a possible explanation for the increased risk of
UGIB and LGIB observed for current users of PPIs in
our study. PPIs are recommended for co-prescription
with antiplatelet therapies among patients at high risk
of gastrointestinal bleeding to reduce this risk [10]. Pa-
tients may be prescribed a PPI because they have a
higher underlying risk of gastrointestinal bleeding, and
may therefore have a higher incidence of bleeding than
those not prescribed a PPI.
Current use of NSAIDs was associated with an increased
risk of UGIB and LGIB. This is in line with results from
previous studies that showed an increased risk of gastro-
intestinal complications associated with the use of NSAIDs
[10, 31]. A recent meta-analysis of randomized studies also
showed a significantly increased risk of upper gastrointes-
tinal complications with all NSAID regimens [32].
The present study has the strength of a large study
population selected from a primary care database that is
representative of the UK population and has been vali-
dated for use in epidemiological studies [18, 21]. It
should be noted that THIN does not report use of over-
the-counter (OTC) medications. However, prescription
medications are free for patients aged 60 years or older
in the UK and health care is easily accessed, which is
likely to encourage prescription rather than OTC medi-
cation use. In our study, most patients (78.6 %) were
aged 60 years or older and therefore misclassification of
drug use due to medications being obtained OTC
should not greatly affect our results. We did not in-
clude bleeding events that occurred while hospitalized,
which might underestimate bleeding rates in this popu-
lation. In common with all observational studies,
another limitation is the possibility of confounding fac-
tors. Although the analyses were adjusted for a number
of factors in order to control for this as much as
possible, it is not possible to control for all potential
confounding factors, so there is a possibility that this
may have affected the study findings.
Conclusions
The results of our study showed that for patients previ-
ously hospitalized for a serious coronary event and treated
with antiplatelet drugs, the incidence of hemorrhagic
stroke and gastrointestinal bleed ranged from 5 to 25
events per 10,000 person-years. Current use of low-dose
ASA was not associated with an increased risk of
hemorrhagic stroke or LGIB, but was associated with a
non-significant increased risk of UGIB. In our study,
however, non-users of ASA were a small subgroup of the
cohort and were for the most part ASA discontinuers and
are likely to have a much higher background risk of
gastrointestinal bleeding than the general population; this
may explain the failure to observe a significantly increased
risk of UGIB and LGIB associated with the use of ASA.
Additionally we showed that combined antithrombotic
therapy with warfarin and antiplatelet drugs greatly in-
creases the risk of hemorrhagic stroke in this population.
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